Chronic Obstructive Pulmonary Disease
Conditions
Keywords
Chronic Obstructive Pulmonary Disease, Bufei Jianpi Granule, Randomized Controlled Trial
Brief summary
This study aims to establish the treatment scheme of Bufei Jianpi granule for early-stage (GOLD stage 1 or 2) chronic obstructive pulmonary disease (COPD), delaying pulmonary function decline and forming high quality evidence.
Detailed description
COPD is a highly prevalent disease, with a prevalence among people 40 years of age or older of 10.1% worldwide and 13.7% in China. COPD has become the third leading cause of death worldwide. More than 70% of patients with COPD are in GOLD stage 1 (mild) or 2 (moderate), with very mild or no apparent respiratory symptoms such as dyspnea. The Tiotropium in Early Chronic Obstructive Pulmonary Disease Patients in China (Tie-COPD) trial was designed to investigate the effect of tiotropium on the FEV1 in COPD patients with GOLD stage 1 or 2. The investigator's previous studies also suggested that traditional Chinese medicine (TCM) has effect on GOLD stage 1 or 2 COPD. This is a multicenter, randomized, double-blind, placebo controlled trial to evaluate the effect of Bufei Jianpi granule for delaying pulmonary function decline in early-stage (GOLD stage 1 or 2) COPD subjects. After a 14-day run-in period, 612 subjects will be randomly assigned to treatment group or control group for 104-week treatment. The primary outcomes include pulmonary function and frequency of acute exacerbation. The secondary outcomes include clinical symptoms, dyspnea, exercise capacity, quality of life and treatment satisfaction. Safety will also be assessed.
Interventions
DRUGBufei Jianpi granule
Bufei Jianpi granule is composed of many kinds of traditional Chinese medicine. The granule will be administered twice daily for five days a week for 104 weeks.
DRUGPlacebo Bufei Jianpi granule
Placebo Bufei Jianpi granule consists of dextrin, bitter and 5% of the Bufei Jianpi granule. The appearance, weight, color and odor of the preparation are the same as those of treatment group. The placebo granule will be administered twice daily for five days a week for 104 weeks.
Sponsors
Jiangsu Province Hospital of Traditional Chinese Medicine
Henan University of Traditional Chinese Medicine
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* A confirmed diagnosis of early-stage (GOLD stage 1 or 2) COPD. * Syndrome differentiation meets criteria of Qi deficiency of the lung syndrome, Qi deficiency of the lung and spleen syndrome or Qi deficiency of the lung and kidney syndrome. * Age ranges from 40 years to 80 years. * With informed consent signed.
Exclusion criteria
* Pregnant and lactating women. * Patients with severe cardiovascular and cerebrovascular diseases. * Patients with severe liver and kidney diseases. * Patients with asthma, bronchiectasis, active pulmonary tuberculosis, pulmonary embolism or other severe respiratory diseases. * Patients with tumor after resection, radiotherapy or chemotherapy in the past 5 years. * Patients with severe neuromuscular disorders, severe arthritis or severe peripheral vascular diseases. * Patients with severe cognitive and psychiatric disorders. * Patients with diabetes. * People who are allergic to the treatment drugs. * Patients who have participated in other clinical studies in the past 4 weeks. * Patients who have experienced one or more acute exacerbation in the past 4 weeks.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| FEV1 | Change from baseline FEV1 at week 26, 52, 78 and 104. | Forced expiratory volume in one second ( FEV1) will be used to assess pulmonary function. |
| Frequency of acute exacerbation | Up to week 104. | Frequency of acute exacerbation will be recorded. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 6MWD | Change from baseline 6MWD at week 13, 26, 39, 52, 65, 78, 91 and 104. | Six-minute walk distance (6MWD) will be conducted to assess exercise capacity. |
| CAT | Change from baseline CAT scores at week 13, 26, 39, 52, 65, 78, 91 and 104. | The COPD assessment test (CAT) is a self-administered questionnaire that measures health-related quality of life. |
| SF-36 | Change from baseline SF-36 scores at week 13, 26, 39, 52, 65, 78, 91 and 104. | The MOS 36-Item Short-Form Health Survey (SF-36) will be used to assess quality of life. |
| Clinical symptom assessment questionnaire | Change from baseline clinical symptom assessment questionnaire scores at week 13, 26, 39, 52, 65, 78, 91 and 104. | Clinical symptom assessment questionnaire of COPD will be used to assess symptom. |
| EQ-5D | Change from baseline EQ-5D scores at week 13, 26, 39, 52, 65, 78, 91 and 104. | EuroQol 5D (EQ-5D) will be used to assess quality of life. |
| mESQ-COPD | Change from baseline mESQ-COPD scores at week 13, 26, 39, 52, 65, 78, 91 and 104. | The modified effectiveness satisfaction questionnaire for COPD (mESQ-COPD) will be used to assess treatment satisfaction. The mESQ-COPD contains 19 items in four domains. mESQ-COPD scores range from 0 to 4 with a decrease in score showing higher treatment satisfaction. |
| mCOPD-PRO | Change from baseline mCOPD-PRO scores at week 13, 26, 39, 52, 65, 78, 91 and 104. | The modified COPD patient-reported outcome scale (mCOPD-PRO) will be used to assess quality of life. The mCOPD-PRO contains 27 items in three domains. mCOPD-PRO scores range from 0 to 4 with a decrease in score showing higher health status. |
| mMRC | Change from baseline mMRC scores at week 13, 26, 39, 52, 65, 78, 91 and 104. | The modified Medical Research Council dyspnoea scale (mMRC) will be used to assess severity of dyspnea. |
Countries
China
Contacts
Primary ContactSuyun Li, Professor
Outcome results
None listed